FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Renal & Urology News11h
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
ConsumerAffairs6d
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
FDA approves nasal spray for treatment-resistant depression
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Scripps News on MSN5d
FDA approves standalone nasal spray to treat depression
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.